KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$128.6 million.

  • Ionis Pharmaceuticals' Profit After Tax rose 845.24% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.3 million, marking a year-over-year increase of 2855.79%. This contributed to the annual value of -$453.9 million for FY2024, which is 2391.87% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Profit After Tax of -$128.6 million as of Q3 2025, which was up 845.24% from $123.6 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Profit After Tax peaked at $224.6 million during Q4 2021, and registered a low of -$147.4 million during Q3 2023.
  • For the 5-year period, Ionis Pharmaceuticals' Profit After Tax averaged around -$66.9 million, with its median value being -$85.3 million (2023).
  • Per our database at Business Quant, Ionis Pharmaceuticals' Profit After Tax tumbled by 102651.41% in 2024 and then skyrocketed by 28644.99% in 2025.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Profit After Tax stood at $224.6 million in 2021, then tumbled by 123.34% to -$52.4 million in 2022, then surged by 82.33% to -$9.3 million in 2023, then plummeted by 1026.51% to -$104.3 million in 2024, then fell by 23.25% to -$128.6 million in 2025.
  • Its last three reported values are -$128.6 million in Q3 2025, $123.6 million for Q2 2025, and -$146.9 million during Q1 2025.